Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient management and clinical decision making in HBV--aims of therapy and what we can achieve.

Antiviral therapy - 1 Jan 2010

Perrillo Robert, Hou Jinlin, Papatheodoridis George, Manns Michael

Abstract excerpt

International treatment guidelines for hepatitis B emphasize alanine aminotransferase (ALT) and serum HBV DNA thresholds, but strict adherence to these markers might lead to missed opportunities in some patients with acquisition in early life. Clinical trials have used improvement in liver histol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype
Share to Hepatitis B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Source

Identifiers

PMID: 21041903
DOI: 10.3851/IMP1623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21041903-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient management and clinical decision making in HBV--aims of therapy and what we can achieve.PMID 21041903Read ↗

Management of chronic hepatitis B: status and challenges beyond treatment guidelines.Semantic proximity Read ↗

Preparing the patient for success: treat or wait?Semantic proximity Read ↗

Virological and serological tools to optimize the management of patients with chronic hepatitis B.Semantic proximity Read ↗

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.Semantic proximity Read ↗

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.Semantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?Semantic proximity Read ↗

Do we need to determine viral genotype in treating chronic hepatitis B?Semantic proximity Read ↗

Therapeutic options for HCV--management of the infected individual.Semantic proximity Read ↗

Management of viral hepatitis B.Semantic proximity Read ↗

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.Semantic proximity Read ↗

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.